Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ALK Abello highlights growth trends in 2010

ALK Abello highlights growth trends in 2010

23rd February 2011

ALK Abello has experienced year-on-year financial growth during 2010, according to the firm's new annual report.

The company's revenue for the 12 months rose by nine percent compared to 2009, reaching a total of 2.14 billion kroner (242.81 million pounds), while reported operating profit grew by ten percent.

During the last year, the firm saw a ten percent rise in allergy vaccine sales, while also conducting a review of its corporate strategy, which will now focus on stimulating sales and expanding its global presence via partnerships.

Next year, ALK expects to see a further five percent growth in allergy treatment sales, which will help it towards its longer-term target of achieving annual revenue of at least three billion kroner by 2015.

Jens Bager, president and chief executive officer of ALK, said: "With continuous growth in our base business and a clear strategy, we have high expectations to the development of ALK in the years to come."

In December 2010, the company purchased additional shares in DBV Technologies in order to support its research into the world's first vaccine for peanut allergy.ADNFCR-8000103-ID-800422315-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.